GenSight Biologics S.A.
SIGHT.PA
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.09
FAIR PRICE
$0.06
MARGIN
$0.03
P/E Ratio
N/A
Div. Yield
N/A
ROE
95.7%
Exceptional
Market Cap
$16M
Small-cap
COMING SOON
Get notified when SIGHT.PA's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Laurence Rodriguez
COUNTRY
FR
HEADQUARTERS
Paris
SECTOR
Healthcare
EXCHANGE
PAR
METHODOLOGY
How we calculate SIGHT.PA's fair price
GenSight Biologics S.A.'s fair price of $0.06 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.09, SIGHT.PA trades 31.0% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting SIGHT.PA's risk profile.
RELATIVE · 30%
Comparing SIGHT.PA's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for SIGHT.PA, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate SIGHT.PA's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for SIGHT.PA.
Explore on BuliosFAQ
What is the fair price of SIGHT.PA?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for GenSight Biologics S.A. is $0.06. At the current market price of $0.09, SIGHT.PA trades 31.0% above its calculated fair value.
Is SIGHT.PA overvalued or undervalued?+
GenSight Biologics S.A. is currently overvalued based on our valuation model. The stock trades at $0.09, which is 31.0% above the fair price of $0.06.
How often is SIGHT.PA's fair price updated?+
We update fair price calculations for SIGHT.PA daily after market close. The current fair price of $0.06 incorporates the latest market data and sector multiples.
What factors affect SIGHT.PA's fair price calculation?+
SIGHT.PA's fair price of $0.06 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 95.7%.
Is SIGHT.PA a good buy right now?+
At $0.09, SIGHT.PA trades 31.0% above our fair value estimate of $0.06. The stock is currently overvalued. ROE stands at 95.7% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does SIGHT.PA pay dividends?+
SIGHT.PA does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.